{
  "trial_id": "NCT01666314",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, histological or cytological confirmation of prostate adenocarcinoma, prior surgical castration or concurrent use of an agent for medical castration, Prostate-Specific Antigen (PSA) levels, progressive disease status, prior therapy history, hypersensitivity to related compounds, use of antiandrogen therapy, use of systemic corticosteroids, prior chemotherapy history.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "gender"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Ethnicity (NIH/OMB)",
        "Race/Ethnicity",
        "Region of Enrollment",
        "Height",
        "Weight",
        "Body Mass Index (BMI)"
      ],
      "remaining_candidate_features": [
        "histological or cytological confirmation of prostate adenocarcinoma",
        "prior surgical castration or concurrent use of an agent for medical castration",
        "Prostate-Specific Antigen (PSA) levels",
        "progressive disease status",
        "prior therapy history",
        "hypersensitivity to related compounds",
        "use of antiandrogen therapy",
        "use of systemic corticosteroids",
        "prior chemotherapy history."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline PSA levels, Prior surgical castration, Use of medical castration agent, Progressive disease status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Height",
        "Weight",
        "Body Mass Index (BMI)"
      ],
      "remaining_candidate_features": [
        "Baseline PSA levels",
        "Prior surgical castration",
        "Use of medical castration agent",
        "Progressive disease status"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Eastern Cooperative Oncology Group (ECOG) Performance Status, Prostate-Specific Antigen (PSA) at screening, Gleason score, Prior therapy for prostate cancer, Duration of prior therapy for prostate cancer.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Body Mass Index (BMI)",
          "Body Mass Index"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Ethnicity (NIH/OMB)",
        "Height",
        "Weight"
      ],
      "remaining_candidate_features": [
        "Eastern Cooperative Oncology Group (ECOG) Performance Status",
        "Prostate-Specific Antigen (PSA) at screening",
        "Gleason score",
        "Prior therapy for prostate cancer",
        "Duration of prior therapy for prostate cancer."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, race, ethnicity, body mass index (BMI), prostate-specific antigen (PSA) level, Gleason score, Eastern Cooperative Oncology Group (ECOG) performance status, prior surgical castration, concurrent use of GnRH analogue, prior neoadjuvant/adjuvant therapy, time since diagnosis of prostate cancer, time since diagnosis of castration-resistant prostate cancer.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Body Mass Index (BMI)",
          "body mass index (BMI)"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Male",
        "Region of Enrollment",
        "Height",
        "Weight"
      ],
      "remaining_candidate_features": [
        "prostate-specific antigen (PSA) level",
        "Gleason score",
        "Eastern Cooperative Oncology Group (ECOG) performance status",
        "prior surgical castration",
        "concurrent use of GnRH analogue",
        "prior neoadjuvant/adjuvant therapy",
        "time since diagnosis of prostate cancer",
        "time since diagnosis of castration-resistant prostate cancer"
      ]
    }
  }
}